Cargando…

Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer

BACKGROUND: Reprogrammed metabolic network is a key hallmark of cancer. Profiling cancer metabolic alterations with spatial signatures not only provides clues for understanding cancer biochemical heterogeneity, but also helps to decipher the possible roles of metabolic reprogramming in cancer develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fukai, Ma, Shuangshuang, Chen, Panpan, Han, Yuhao, Liu, Zhaoyun, Wang, Xinzhao, Sun, Chenglong, Yu, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149015/ https://www.ncbi.nlm.nih.gov/pubmed/37120513 http://dx.doi.org/10.1186/s12935-023-02908-8

Ejemplares similares

The treatment role of Cyperus rotundus L. to triple-negative breast cancer cells
por: Wang, Fukai, et al.
Publicado: (2019)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
por: Wang, Xinzhao, et al.
Publicado: (2021)

Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway
por: Shao, Wenna, et al.
Publicado: (2023)

Cell metabolomics to study the function mechanism of Cyperus rotundus L. on triple-negative breast cancer cells
por: Ma, Shuangshuang, et al.
Publicado: (2020)

Metabolic Reprogramming in Kidney Diseases: Evidence and Therapeutic Opportunities
por: Li, Yin, et al.
Publicado: (2021)

Mass spectrometry imaging-based metabolomics to visualize the spatially resolved reprogramming of carnitine metabolism in breast cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Metabolic reprogramming during hepatitis B disease progression offers novel diagnostic and therapeutic opportunities
por: Masson, Jesse JR, et al.
Publicado: (2017)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming
por: Márquez, Javier, et al.
Publicado: (2021)

Metabolic reprogramming in cancer: Mechanisms and therapeutics
por: Nong, Shiqi, et al.
Publicado: (2023)

Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities
por: Ge, Tongxin, et al.
Publicado: (2022)

Reprogramming of fatty acid metabolism in cancer
por: Koundouros, Nikos, et al.
Publicado: (2019)

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
por: WANG, XINZHAO, et al.
Publicado: (2015)

Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
por: Yuan, Chenxi, et al.
Publicado: (2019)

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer
por: Xu, Huan, et al.
Publicado: (2021)

Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities
por: De Matteis, Serena, et al.
Publicado: (2018)

A Nomogram Based on Hematological Parameters and Clinicopathological Characteristics for Predicting Local–Regional Recurrence After Breast-Conserving Therapy
por: Sun, Luhao, et al.
Publicado: (2022)

Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer
por: Liu, Zhaoyun, et al.
Publicado: (2017)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Li, Chao, et al.
Publicado: (2021)

Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities
por: Alcaraz, Jordi, et al.
Publicado: (2021)

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities
por: Neitzel, Carina, et al.
Publicado: (2020)

Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy
por: Sun, Nai-Yun, et al.
Publicado: (2020)

Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities
por: Alramadhani, Dina, et al.
Publicado: (2022)

Metabolic reprogramming enables the auxiliary diagnosis of breast cancer by automated breast volume scanner
por: Liu, Jianjun, et al.
Publicado: (2022)

Preoperative tumor biopsy results in more detected sentinel nodes than intraoperative biopsy in breast cancer patients
por: Yuan, Chenxi, et al.
Publicado: (2020)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Targeting Lipid Metabolic Reprogramming as Anticancer Therapeutics
por: Cha, Ji-Young, et al.
Publicado: (2016)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
por: Pang, Yuyang, et al.
Publicado: (2023)

The Role of Fatty Acid Oxidation in the Metabolic Reprograming of Activated T-Cells
por: Byersdorfer, Craig Alan
Publicado: (2014)

Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
por: Jin, Hao-Ran, et al.
Publicado: (2023)

Boosting NAD: An opportunity for metabolic reprogramming of Th17 cells in psoriatic disease
por: Reali, Eva
Publicado: (2023)

Astrocyte Reprogramming in Stroke: Opportunities and Challenges
por: Peng, Zhouzhou, et al.
Publicado: (2022)

Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth
por: Cox, Andrew G., et al.
Publicado: (2016)

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism
por: Dai, Weixing, et al.
Publicado: (2022)

Adipocytes promote pancreatic cancer migration and invasion through fatty acid metabolic reprogramming
por: Cai, Zhiwei, et al.
Publicado: (2023)

Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?
por: Mozihim, Azilleo Kristo, et al.
Publicado: (2022)

Metabolic reprogramming: the emerging concept and associated therapeutic strategies
por: Yoshida, Go J.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bp6hpbuc94vo23507r06qma10h